JP MORGAN/CALL/ELI LILLY & CO/1320/0.01/16.01.26 | Real-time Bid/Ask 17:56:16 31/05/2024 BST | ||
| 0.41 EUR / 0.43 EUR | +2.44% |
|
| Current month | +13.89% | ||
| 1 month | +13.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.41 | 0.00% |
| 30/05/24 | 0.41 | +2.50% |
| 29/05/24 | 0.4 | -2.44% |
| 28/05/24 | 0.41 | -2.38% |
| 27/05/24 | 0.42 | 0.00% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 10:01 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK7KCQ |
| ISIN | DE000JK7KCQ2 |
| Date issued | 10/04/2024 |
| Strike | 1,320 $ |
| Maturity | 16/01/2026 (595 Days) |
| Parity | 100 : 1 |
| Emission price | 0.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.43 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.02 € |
| Spread % | 4.55% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
815.1
USD
Average target price
852.5
USD
Spread / Average Target
+4.60%
- Stock Market
- Warrants
- Warrant
